LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Prime Medicine, Inc. today and set a price target of $6.00.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Jubinville, PhD is ranked #511 out of 12332 analysts.
In addition to LifeSci Capital, Prime Medicine, Inc. also received a Buy from H.C. Wainwright’s Arthur He CFA in a report issued on July 9. However, on July 8, Morgan Stanley maintained a Hold rating on Prime Medicine, Inc. (NASDAQ: PRME).
Based on Prime Medicine, Inc.’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $856 thousand and a GAAP net loss of $49.12 million. In comparison, last year the company earned a revenue of $1.45 million and had a GAAP net loss of $51.89 million
